Hepatitis Drugs Market to Surpass USD 32,906 Mn by 2033

Hepatitis Drugs Market Reaches USD 26,380 Million in 2026, Driven by Rising Hepatitis Prevalence and Expanding Access to Antiviral Treatment

Advancements in Antiviral Therapies and Increasing Screening Initiatives to Drive Hepatitis Drugs Market to USD 32,906 Mn by 2033 at 3.2% CAGR – Coherent Market Insights

Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type  (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 26,380 Mn in 2026, and is projected to exhibit a CAGR of 3.2% over the forecast period (2026 - 2033), as highlighted in a new report published by Coherent Market Insights.

Increasing government initiatives aimed at expanding hepatitis testing, treatment access, and subsidized medicine coverage are expected to drive market growth. For instance, in January 2026, the Australian Government Department of Health, Disability and Ageing confirmed continued funding for a national hepatitis C point-of-care testing program, hepatitis C education campaigns, and the Test, Treat and Go program in remote Aboriginal and Torres Strait Islander communities. These initiatives focus on improving testing, treatment uptake, and linkage to care. In March 2026, Australia’s Minister for Health also highlighted that curative hepatitis C treatments are available through the Pharmaceutical Benefits Scheme, providing subsidized access and improving outcomes for tens of thousands of Australians. Such publicly funded initiatives are expected to increase diagnosis and antiviral treatment uptake, thereby supporting growth of the hepatitis drugs market.

Moreover, the future availability of hepatitis C drugs is expected to increase due to continued development of next-generation direct-acting antiviral therapies. Market growth is being supported by interferon-free fixed-dose combinations that target multiple stages of the hepatitis C virus replication cycle and may provide shorter treatment durations, high efficacy, and a lower risk of drug–drug interactions. For instance, in June 2026, Atea Pharmaceuticals completed patient enrollment in the Phase 3 C-FORWARD trial evaluating a fixed-dose combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for treating chronic hepatitis C. The trial enrolled more than 880 treatment-naïve patients across 17 countries and compares the bemnifosbuvir–ruzasvir combination with sofosbuvir–velpatasvir. The investigational combination is administered once daily for eight weeks in patients without cirrhosis and for 12 weeks in patients with compensated cirrhosis, with Phase 3 topline results expected around the end of 2026.

Global Hepatitis Drugs Market – Opportunities

• Expansion of Hepatitis B Treatment Coverage

The largest opportunity lies in treating the substantial undiagnosed and untreated hepatitis B population. WHO estimates that approximately 240 million people were living with chronic hepatitis B in 2024, but fewer than 5% were receiving treatment, even though around half may be eligible under current WHO guidelines. Expanding screening, treatment eligibility, reimbursement, and public procurement could significantly increase demand for nucleos(t)ide analogues and other HBV therapies. (Source: WHO)

• Next-Generation and Shorter-Course HCV Combinations

Opportunities exist for pan-genotypic, once-daily and shorter-duration DAA combinations that reduce pill burden, monitoring requirements, drug interactions and treatment failure. New therapies could particularly address patients with cirrhosis, previous treatment failure, renal impairment, HIV coinfection or resistant HCV variants. WHO already recommends pan-genotypic DAAs for adults, adolescents and children aged three years and above, supporting broad addressable demand.

• Emerging Hepatitis D Treatment Segment

Hepatitis D represents an emerging specialty-drug opportunity because treatment options have historically been extremely limited. On May 22, 2026, the U.S. FDA approved Hepcludex for chronic HDV infection, making it the first FDA-approved treatment for this condition. The approval establishes a commercial pathway for additional entry inhibitors, immune therapies and combination treatments targeting HDV. ( Source: U.S.FDA)

To know the latest trends and insights related to Hepatitis Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hepatitis-drugs-market-2977

Additionally, on 28^th July 2018 (World Hepatitis Day) the National Viral Hepatitis Control Program was launched by the Ministry of Health and Family Welfare, Government of India. It is an integrated initiative for the prevention and control of viral hepatitis in India to achieve Sustainable Development Goal (SDG), which aims to end viral hepatitis by 2030.

Global Hepatitis Drugs Market Trends

• Shift from Lifelong Hepatitis B Suppression to Functional-Cure Therapies

Hepatitis B drug development is increasingly shifting from lifelong viral suppression toward finite-duration treatments capable of achieving a functional cure. New antisense oligonucleotides are designed to reduce viral RNA, hepatitis B surface antigen and viral replication while restoring immune control. In May 2026, GSK reported pooled Phase III results showing that six months of bepirovirsen treatment achieved a 19% functional-cure rate in the overall study population and 26% among patients with lower baseline HBsAg levels, compared with 0% in the placebo groups. The drug was also accepted for FDA priority review, demonstrating growing regulatory momentum for functional-cure therapies.

• Development of Next-Generation Fixed-Dose Hepatitis C Combinations

Companies are developing new fixed-dose direct-acting antiviral combinations that seek to differentiate themselves through shorter treatment courses, broad genotype coverage, improved resistance profiles and fewer drug–drug interactions. In June 2026, Atea Pharmaceuticals completed enrolment in the Phase III C-FORWARD trial evaluating bemnifosbuvir and ruzasvir against the established sofosbuvir–velpatasvir regimen. More than 880 treatment-naïve patients were enrolled across 17 countries. In May 2026, the company also presented drug-interaction data supporting the potential use of the combination among patients receiving other medicines.

• Increasing Availability of Targeted Hepatitis D Treatments

Hepatitis D is emerging as an important specialty-drug segment as companies and regulators address a disease that historically had few effective treatment options. On May 22, 2026, the U.S. FDA approved Hepcludex, or bulevirtide-gmod, for adults with chronic hepatitis D without cirrhosis or with compensated cirrhosis. It became the first FDA-approved treatment specifically for chronic HDV infection. In the supporting Phase III trial, 48% of treated patients achieved the combined virologic and liver-enzyme response at Week 48, compared with 2% in the delayed-treatment group.

• Movement Toward Multi-Mechanism Combination Therapy for Hepatitis D

Hepatitis D pipelines are moving beyond single-target drugs toward combinations that act through different mechanisms. These include monoclonal antibodies that target hepatitis B surface antigen and small interfering RNA therapies that reduce viral-protein production. In a 2026 update, Vir Biotechnology reported that the combination of tobevibart and elebsiran achieved undetectable HDV RNA in 88% of evaluable participants at Week 96 in the Phase II SOLSTICE study. The combination is being evaluated in the Phase III ECLIPSE programme, including patients who remain unsuppressed after bulevirtide treatment.

• Expansion of Drug Development into Hepatitis E

The hepatitis drug pipeline is expanding beyond hepatitis B, C and D into hepatitis E, particularly as companies seek treatments for patients at risk of persistent or severe infection. On July 14, 2026, Atea Pharmaceuticals initiated a first-in-human Phase I clinical trial of AT-587, an investigational direct-acting antiviral for hepatitis E virus. The study is evaluating its safety, tolerability and pharmacokinetics in healthy volunteers. Atea identified AT-587 as a potential first-in-class treatment in an area where no approved HEV-specific therapies are currently available.

• Simplified Treatment Eligibility and Decentralized Drug Delivery

Simplified prescribing, less monitoring requirements, and therapy delivery through primary care and community settings are further trends in the industry. This strategy can increase the number of people with hepatitis who receive treatment, especially in low- and middle-income nations. In February 2026, WHO published consolidated hepatitis B and C guidance that simplified eligibility and monitoring for hepatitis B antiviral treatment, endorsed curative direct-acting antivirals for hepatitis C and promoted integration with primary care, HIV and tuberculosis programmes.

• Accelerated and Parallel Regulatory Review Across Major Markets

Promising hepatitis medicines are increasingly being submitted simultaneously across the U.S., Europe and major Asian markets to shorten the time between clinical development and commercial availability. In 2026, GSK’s bepirovirsen was accepted for regulatory review in the United States, European Union, Japan and China. The U.S. FDA granted priority review and Breakthrough Therapy Designation, while GSK began launch preparations based on positive Phase III functional-cure results. This trend is expected to support faster international commercialization of innovative hepatitis therapies.

Key Development

• In May 2026, the U.S. FDA granted accelerated approval to Gilead Sciences’ Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus infection, making it the first and only approved HDV treatment in the United States. The decision was supported by Phase 3 MYR301 data showing significant virologic and biochemical responses at Week 48. Hepcludex blocks HDV and HBV entry into liver cells and is administered once daily by subcutaneous injection. (Source: Gilead Sciences, Inc.)
• In June 2026, Atea Pharmaceuticals, a clinical stage biopharmaceutical company completed enrolment in its Phase III C-FORWARD trial evaluating the fixed-dose combination of bemnifosbuvir and ruzasvir for chronic hepatitis C. The trial enrolled more than 880 treatment-naïve patients across 17 countries and compares the investigational regimen with sofosbuvir–velpatasvir. The combination is being developed as a potentially shorter, pan-genotypic treatment with limited food restrictions and drug-interaction risks.
• In July 2026, Atea Pharmaceuticals, a clinical stage biopharmaceutical company initiated a first-in-human Phase I study of AT-587, an investigational oral nucleotide analogue for hepatitis E virus infection. The study is assessing safety, tolerability and pharmacokinetics in healthy volunteers. AT-587 represents an important pipeline advancement because no HEV-specific antiviral therapy is currently approved, leaving immunocompromised patients and transplant recipients with a significant unmet treatment need. (Source: Atea Pharmaceuticals)

Key Takeaways of the Hepatitis Drugs Market

• The global hepatitis drugs market is expected to expand at a CAGR of 3.2% during the forecast period (2026–2033), owing to increasing government initiatives and drug development for hepatitis treatment. 
• Among disease type, Hepatitis C is expected to hold major revenue share in 2026, owing to increasing global prevalence of hepatitis C.
• Major players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.